The PennZone

  • Home
  • Business
  • Health
  • Financial
  • Construction
  • Education
  • Non-profit
  • Media
  • Books

purelyIV Launches Niagen® IV Therapy – A Breakthrough in NAD+ Cellular Wellness
The PennZone/10312393

Trending...
  • The Evolution of the BDCV Platform: Empowering Mental Health & Wellness
  • Postmortem Pathology Offers Expert Autopsy Services with Dignity and Accuracy
  • Meet &insurance: The New Amenity Platform
Purelyivt Niagen Nad 360
Metro Detroit's leading mobile IV therapy provider introduces pharmaceutical-grade Niagen® infusions, offering a faster, more efficient, and more comfortable way to boost NAD+ levels at home.

ROCHESTER HILLS, Mich. - PennZone -- purelyIV, Metro Detroit's leading mobile IV therapy provider, is proud to announce the launch of Niagen® IV Therapy, a groundbreaking new service designed to efficiently boost NAD+ levels. This innovative treatment uses pharmaceutical-grade nicotinamide riboside chloride (NR) to deliver a faster, more comfortable NAD+ replenishment experience compared to traditional NAD+ IV infusions.

Niagen® IV Therapy offers clients a cutting-edge approach to cellular health and wellness. Clinical studies show that Niagen® infusions raise whole-blood NAD+ levels 20% higher than standard NAD+ IV treatments and achieve peak levels within just three hours—while requiring 75% less infusion time. Treatments are typically completed in 30–45 minutes, allowing for a more convenient experience with fewer side effects.

More on The PennZone
  • Colonna Contempo Presents Offcuts, Cat Russell's Meditative Collages Find Meaning in the Fragments
  • Jewellok Unveils Cutting-Edge Specialty Gas Changeover Manifolds to Revolutionize Industrial and Medical Gas Delivery
  • Press Snooze on Summer: 8 Inns Team Up to Help Guests Sleep In
  • On the 30th anniversary of the Netscape IPO the inventor of the banner ad warns: "Trouble ahead."
  • ROCKET PHARMACEUTICALS (NASDAQ: RCKT) CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Investors to Inquire About a Securities Fraud Class Action by August 11, 2025

"Niagen® IV Therapy represents the next evolution of NAD+ boosting wellness," said Erin Boumansour, co-founder and lead practitioner at purelyIV. "We are excited to bring this advanced therapy to Metro Detroit, offering our clients an efficient and scientifically supported option to enhance energy, support cognitive health, and promote healthy aging—all delivered in the comfort of their home or office."

purelyIV's licensed nurses administer Niagen® IV infusions in 500mg and 1000mg doses with 500ml of fluids and electrolytes. Clients can also choose add-on options like Niagen® IV Push and Niagen® Shots for a quick, convenient boost during other IV treatments.

With its mobile, in-home service model and commitment to clinical excellence, purelyIV continues to lead the way in providing premium IV therapy solutions designed to meet the unique wellness goals of each client.

To learn more about Niagen® IV Therapy or to schedule an appointment, visit https://purelyiv.com/niagen-iv-therapy.

Contact
Michael Boumansour
***@purelyiv.com


Source: purelyIV

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Former Irvine Mayor Farrah Khan Joins Tech Coast Venture Network Board
  • 123Invent Inventor Develops Newly Designed Head Covering
  • 123Invent Inventor Develops New Appliance Power Saver (BDH-1037)
  • DT Digital Relaunches as Redouble Digital, Expanding from Freelance Operation to Full-Service E-commerce Marketing Agency
  • TL International Group Ltd Terminates Franchise Agreement with Apollo Rent A Car
  • TSWHZC Addresses Recent Malicious Reports and Reaffirms Commitment to Regulatory Compliance and User Protection
  • Introducing Lick Scented Bath Oils: Transform Your Bath into a Luxurious Escape
  • Free Printable Math Bingo Cards Released for Teachers, Parents, and Students
  • Dilworth Paxson LLP Welcomes New Partner, Lauren Sheller Insana
  • Voices Across the Men's Health Network:
  • Bent Danholm To Be Featured On Global Podcast Network In Live Interview
  • AdvoCast Expands Leadership in Strategic Comms with New Role Producing "Communication Breakdown" Podcast
  • Rocket.Chat assessed "Awardable" for Department of Defense work in the CDAO's Tradewinds Solutions Marketplace
  • David L. Lawrence Convention Center Selects showNets for 3-Year Internet & Wi-Fi Network Management Partnership
  • Success for Global Communications Leader IQSTEL, Inc. Growing From $13 Million Revenue in 2018 to Nearly $300 Million Last Year
  • YPTC Wins #1 Best Place to Work in Philadelphia
  • Artbound: "The Cheech" Awarded Two 2025 LA Area EMMY Awards — Honored in ARTS & MUSIC COMPOSITION
  • Leading Retirement Expert Michael J. Seibert Featured on CNBC
  • Rising Conservative Star Jordan Brace Emerges as Influential Political Voice with Elite Washington Connections
  • RCKT DEADLINE REMINDER: Berger Montague Reminds Rocket Pharmaceuticals (NASDAQ: RCKT) Investors of Important Class Action Lawsuit Deadline

Popular on PennZone

  • VIP Vacations Recognized as a 2024 Top Selling Travel Agency by the Jamaica Tourism Board - 119
  • SeedList Launching Institutional Crypto Crowdfunding Project to Empower Retail Investors and Disrupt the VC-Dominated Crypto Fundraising Landscape
  • Pyro Marketing Opens New Digital Marketing Company to Power Growth for Fitness and Ecommerce Brands
  • Be Part of the World's Largest Art Biennale | Moons, Castles, Trees | Copenhagen Chronotopes
  • Exelon Leader Tamla Olivier Named 2025 Technologist of the Year by Waves of Change STEM Conference
  • Dr. Harmon Completes Prestigious Zygomatic Implant Residency in Brazil
  • Rent Like A Champion Acquires CollegeWeekends
  • Ignazio Arces Wins Silver Stevie Award in New York as Culture Transformation Leader of the Year
  • GreenPal Empowers Lawn Care Pros Leveraging AI, Surpasses 5 Million Transactions
  • Real Estate Experts Highlight Jersey Shore as a Smart Buy in 2025

Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us